Ga68 PET SCAN
NETSPOT®
Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection) for the evaluation of neuroendocrine tumours (“NETs”). NETSPOT® is the first and only kit for the preparation of gallium (68Ga) oxodotreotide injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEPNET) for localizing primary tumours and their metastases.
Gallium (68Ga) oxodotreotide injection
| NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection) PRODUCT MONOGRAPH (ENG) PRODUCT MONOGRAPH (FRE) |
|
|---|---|
| Brand Name | NETSPOT® |
| Generic Name | kit for the preparation of gallium (68Ga) oxodotreotide injection |
| Dosage | In adult patients – The recommended amount of radioactivity to be administered for PET imaging is up to 2 MBq/kg of body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi). |
| Indication | NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs). |
| Tumour Type | NETs |
| Contraindications | None |
ACCESS TO NETSPOT®
Health Canada Approval of NETSPOT – PRESS RELEASE
NETSPOT® – Health Canada Approved and Now Available. Kit for the preparation of gallium (68Ga) oxodotreotide injection
Advanced Accelerator Applications S.A. (AAA), a Novartis company is pleased to announce that Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection).
INDICATION
NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).
FOR MORE INFORMATION:
Please consult the Product Monograph at https://www.adacap.com/our-products/ for important product information relating to dosing information, drug interactions and adverse reactions. The Product Monograph is also available by calling AAA Customer Service at Tel: 1-844-367-3222.
ACCESS TO NETSPOT® IN CANADA
NETSPOT is available at the following clinic in BC. Patients will require a physician referral (referral form is available on their website at initiomedical.ca). Cost is $5,200.
Initio Medical Group Inc.
#300-3185 Willingdon Green, Burnaby, BC, V5G 4P3
Phone: 604-678-9274
Fax: 604-678-9274
QEII Health Sciences Centre
1276 South Park, Halifax, NS
Sunnybrook Health Sciences Centre
3075 Bayview Avenue, Toronto, ON
KMH Labs
2075 Hadwen Road, Mississauga, ON
CISSS de Laval
1755, boul. René-Laennec, Laval, QC
CIUSSS MCQ – Trois-Rivieres
1991, Boulevard du Carmel, Trois-Rivieres, QC
CHU – Sainte Justine
3175 chemin de la Cote-Sainte-Catherine, Montreal, QC
CISSS CA – Secteur Alphonse- Desjardins (Lévis)
100 Rue Monseigneur-Bourget, Lewis, QC
CIUSSS Saguenay Lac-St-Jean
305 Rue St-Vallier, Chicoutimi, QC